Enhancing insulin oral absorption by using mucoadhesive nanoparticles loaded with LMWP-linked insulin conjugates

Journal of Controlled Release

Volumn 233, Issue , 2016, Pages 181-190

  Sheng, Jianyong ^a   He, Huining ^b   Han, Limei ^a   Qin, Jing ^a   Chen, Sunhui ^b   Ru, Ge ^a   Li, Ruixiang ^a   Yang, Pei ^a   Wang, Jianxin ^a   Yang, Victor C ^b,c  

^a FUDAN UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cell penetrating peptide; Insulin; Low molecular weight protamine; Mucoadhesion; Nanoparticles; Oral delivery

Indexed keywords

BODY FLUIDS; DRUG PRODUCTS; MOLECULAR WEIGHT; NANOPARTICLES; PEPTIDES; PROTEINS;

CELL-PENETRATING PEPTIDE; ENZYMATIC DEGRADATION; GASTROINTESTINAL TRACT; LOW MOLECULAR WEIGHT PROTAMINES; MACROMOLECULAR THERAPEUTICS; MUCOADHESION; ORAL DELIVERY; ORAL INSULIN DELIVERY;

INSULIN;

CELL PENETRATING PEPTIDE; CHITOSAN NANOPARTICLE; INSULIN; LOW MOLECULAR WEIGHT PROTAMINE; MUCOADHESIVE NANOPARTICLE; N TRIMETHYL CHITOSAN CHLORIDE; NANOPARTICLE; POLYGLACTIN; PROTAMINE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; CHITOSAN; LACTIC ACID; N-TRIMETHYL CHITOSAN CHLORIDE; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DRUG ABSORPTION; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; DRUG UPTAKE; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA; NONHUMAN; PRIORITY JOURNAL; RAT; ADHESION; ANALYSIS; ANIMAL; BLOOD; CHEMISTRY; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; INTESTINE ABSORPTION; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; TUMOR CELL LINE; WISTAR RAT;

ADHESIVENESS; ADMINISTRATION, ORAL; ANIMALS; BLOOD GLUCOSE; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; CHITOSAN; DIABETES MELLITUS, EXPERIMENTAL; DRUG LIBERATION; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; LACTIC ACID; MALE; NANOPARTICLES; POLYGLYCOLIC ACID; PROTAMINES; RATS, WISTAR;

EID: 84977615801     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2016.05.015     Document Type: Article

References (46)

1. [1] Yuan, F., Quan, L., Cui, L., Goldring, S.R., Wang, D., Development of macromolecular prodrug for rheumatoid arthritis. Adv. Drug Deliv. Rev. 64:12 (2012), 1205–1219.
2. [2] Noguchi, T., Ritter, G., Nishikawa, H., Antibody-based therapy in colorectal cancer. Immunotherapy-Uk 5:5 (2013), 533–545.
3. [3] Robert, R., Wark, K.L., Engineered antibody approaches for Alzheimer's disease immunotherapy. Arch. Biochem. Biophys. 526:2 (2012), 132–138.
4. [4] Lagarce, F., Groo, A., Saulnier, P., Gimel, J., Gravier, J., Ailhas, C., Benoit, J., Fate of paclitaxel lipid nanocapsules in intestinal mucus in view of their oral delivery. Int. J. Nanomedicine, 4291, 2013.
5. [5] Ensign, L.M., Cone, R., Hanes, J., Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64:6 (2012), 557–570.
6. [6] Smart, A.L., Gaisford, S., Basit, A.W., Oral peptide and protein delivery: intestinal obstacles and commercial prospects. Expert Opin. Drug Deliv. 11:8 (2014), 1323–1335.
7. [7] Shan, W., Zhu, X., Liu, M., Li, L., Zhong, J., Sun, W., Zhang, Z., Huang, Y., Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by self-assembled nanoparticles for oral delivery of insulin. ACS Nano 9:3 (2015), 2345–2356.
8. [8] Kriegel, C., Attarwala, H., Amiji, M., Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract. Adv. Drug Deliv. Rev. 65:6 (2013), 891–901.
9. [9] Chen, M., Sonaje, K., Chen, K., Sung, H., A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 32:36 (2011), 9826–9838.
10. [10] Yin, L., Ding, J., He, C., Cui, L., Tang, C., Yin, C., Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 30:29 (2009), 5691–5700.
11. [11] Reix, N., Parat, A., Seyfritz, E., Van Der Werf, R., Epure, V., Ebel, N., Danicher, L., Marchioni, E., Jeandidier, N., Pinget, M., Frère, Y., Sigrist, S., In vitro uptake evaluation in Caco-2 cells and in vivo results in diabetic rats of insulin-loaded PLGA nanoparticles. Int. J. Pharm. 437:1–2 (2012), 213–220.
12. [12] Zhang, Y., Yang, Z., Hu, X., Zhang, L., Li, F., Li, M., Tang, X., Xiao, W., Development and evaluation of mucoadhesive nanoparticles based on thiolated eudragit for oral delivery of protein drugs. J. Nanopart. Res., 17(2), 2015.
13. [13] Zambito, Y., Felice, F., Fabiano, A., Di Stefano, R., Di Colo, G., Mucoadhesive nanoparticles made of thiolated quaternary chitosan crosslinked with hyaluronan. Carbohydr. Polym. 92:1 (2013), 33–39.
14. [14] Sheng, J., Han, L., Qin, J., Ru, G., Li, R., Wu, L., Cui, D., Yang, P., He, Y., Wang, J., N-trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption. ACS Appl. Mater. Interfaces 7:28 (2015), 15430–15441.
15. [15] Liang, J.F., Yang, V.C., Insulin-cell penetrating peptide hybrids with improved intestinal absorption efficiency. Biochem. Biophys. Res. Commun. 335:3 (2005), 734–738.
16. [16] He, H., Sheng, J., David, A.E., Kwon, Y.M., Zhang, J., Huang, Y., Wang, J., Yang, V.C., The use of low molecular weight protamine chemical chimera to enhance monomeric insulin intestinal absorption. Biomaterials 34:31 (2013), 7733–7743.
17. [17] Ye, J., Shin, M.C., Liang, Q., He, H., Yang, V.C., 15 years of attempts: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting. J. Control. Release 205 (2015), 58–69.
18. [18] Park, Y.J., Nontoxic membrane translocation peptide from protamine, low molecular weight protamine (LMWP), for enhanced intracellular protein delivery: in vitro and in vivo study. FASEB J., 2005.
19. [19] Chang, L.C., Lee, H.F., Yang, Z., Yang, V.C., Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (i): preparation and characterization. AAPS PharmSci, 3(3), 2001, E17.
20. [20] Chang, L.C., Liang, J.F., Lee, H.F., Lee, L.M., Yang, V.C., Low molecular weight protamine (LMWP) as nontoxic heparin/low molecular weight heparin antidote (ii): in vitro evaluation of efficacy and toxicity. AAPS PharmSci, 3(3), 2001, E18.
21. [21] Lee, L.M., Chang, L.C., Wrobleski, S., Wakefield, T.W., Yang, V.C., Low molecular weight protamine as nontoxic heparin/low molecular weight heparin antidote (iii): preliminary in vivo evaluation of efficacy and toxicity using a canine model. AAPS PharmSci, 3(3), 2001, E19.
22. [22] Lin, Y., Sonaje, K., Lin, K.M., Juang, J., Mi, F., Yang, H., Sung, H., Multi-ion-crosslinked nanoparticles with pH-responsive characteristics for oral delivery of protein drugs. J. Control. Release 132:2 (2008), 141–149.
23. [23] Kotze, A.F., Luessen, H.L., de Leeuw, B.J., de Boer, A.G., Verhoef, J.C., Junginger, H.E., Comparison of the effect of different chitosan salts and n-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). J. Control. Release 51:1 (1998), 35–46.
24. [24] Sadeghi, A., Dorkoosh, F., Avadi, M., Weinhold, M., Bayat, A., Delie, F., Gurny, R., Larijani, B., Rafieetehrani, M., Junginger, H., Permeation enhancer effect of chitosan and chitosan derivatives: comparison of formulations as soluble polymers and nanoparticulate systems on insulin absorption in Caco-2 cells. Eur. J. Pharm. Biopharm. 70:1 (2008), 270–278.
25. [25] Guo, C., Gemeinhart, R.A., Understanding the adsorption mechanism of chitosan onto poly(lactide-co-glycolide) particles. Eur. J. Pharm. Biopharm. 70:2 (2008), 597–604.
26. [26] Zhang, X., Sun, M., Zheng, A., Cao, D., Bi, Y., Sun, J., Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur. J. Pharm. Sci. 45:5 (2012), 632–638.
27. [27] Sonaje, K., Lin, K., Wang, J., Mi, F., Chen, C., Juang, J., Sung, H., Self-assembled pH-sensitive nanoparticles: a platform for oral delivery of protein drugs. Adv. Funct. Mater. 20:21 (2010), 3695–3700.
28. [28] Mukhopadhyay, P., Sarkar, K., Chakraborty, M., Bhattacharya, S., Mishra, R., Kundu, P.P., Oral insulin delivery by self-assembled chitosan nanoparticles: in vitro and in vivo studies in diabetic animal model. Mat. Sci. Eng. C-Mater. 33:1 (2013), 376–382.
29. [29] Alqahtani, S., Simon, L., Astete, C.E., Alayoubi, A., Sylvester, P.W., Nazzal, S., Shen, Y., Xu, Z., Kaddoumi, A., Sabliov, C.M., Cellular uptake, antioxidant and antiproliferative activity of entrapped alpha-tocopherol and gamma-tocotrienol in poly (lactic-co-glycolic) acid (PLGA) and chitosan covered PLGA nanoparticles (PLGA-CHI). J. Colloid Interface Sci. 445 (2015), 243–251.
30. [30] Kotze, A.F., Thanou, M.M., Luessen, H.L., de Boer, B.G., Verhoef, J.C., Junginger, H.E., Effect of the degree of quaternization of n-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). Eur. J. Pharm. Biopharm. 47:3 (1999), 269–274.
31. [31] Behrens, I., Stenberg, P., Artursson, P., Kissel, T., Transport of lipophilic drug molecules in a new mucus-secreting cell culture model based on HT29-mtx cells. Pharm. Res. 18:8 (2001), 1138–1145.
32. [32] Jin, Y., Song, Y., Zhu, X., Zhou, D., Chen, C., Zhang, Z., Huang, Y., Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33:5 (2012), 1573–1582.
33. [33] Li, X., Guo, S., Zhu, C., Zhu, Q., Gan, Y., Rantanen, J., Rahbek, U.L., Hovgaard, L., Yang, M., Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials 34:37 (2013), 9678–9687.
34. [34] Chen, M., Mi, F., Liao, Z., Hsiao, C., Sonaje, K., Chung, M., Hsu, L., Sung, H., Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv. Drug Deliv. Rev. 65:6 (2013), 865–879.
35. [35] Behrens, I., Pena, A.I., Alonso, M.J., Kissel, T., Comparative uptake studies of bioadhesive and non-bioadhesive nanoparticles in human intestinal cell lines and rats: the effect of mucus on particle adsorption and transport. Pharm. Res. 19:8 (2002), 1185–1193.
36. [36] Lai, S.K., Wang, Y., Wirtz, D., Hanes, J., Micro- and macrorheology of mucus. Adv. Drug Deliv. Rev. 61:2 (2009), 86–100.
37. [37] Larhed, A.W., Artursson, P., Bjork, E., The influence of intestinal mucus components on the diffusion of drugs. Pharm. Res. 15:1 (1998), 66–71.
38. [38] Maisel, K., Ensign, L., Reddy, M., Cone, R., Hanes, J., Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse. J. Control. Release 197:10 (2015), 48–57.
39. [39] Yang, M., Lai, S.K., Wang, Y.Y., Zhong, W., Happe, C., Zhang, M., Fu, J., Hanes, J., Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus. Angew. Chem. Int. Ed. Eng. 50:11 (2011), 2597–2600.
40. [40] Gamboa, J.M., Leong, K.W., In vitro and in vivo models for the study of oral delivery of nanoparticles. Adv. Drug Deliv. Rev. 65:6 (2013), 800–810.
41. [41] Artursson, P., Palm, K., Luthman, K., Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 64 (2012), 280–289.
42. [42] Jones, A.T., Sayers, E.J., Cell entry of cell penetrating peptides: tales of tails wagging dogs. J. Control. Release 161:2 (2012), 582–591.
43. [43] Patel, L.N., Zaro, J.L., Shen, W., Cell penetrating peptides: intracellular pathways and pharmaceutical perspectives. Pharm. Res.-Dordr 24:11 (2007), 1977–1992.
44. [44] Pontier, C., Pachot, J., Botham, R., Lenfant, B., Arnaud, P., Ht29-mtx and Caco-2/TC7 monolayers as predictive models for human intestinal absorption: role of the mucus layer. J. Pharm. Sci. 90:10 (2001), 1608–1619.
45. [45] Hilgendorf, C., Spahn-Langguth, H., Regardh, C.G., Lipka, E., Amidon, G.L., Langguth, P., Caco-2 versus Caco-2/HT29-mtx co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport. J. Pharm. Sci. 89:1 (2000), 63–75.
46. [46] Hinds, K.D., Kim, S.W., Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. 54:4 (2002), 505–530.